Volasertib preclinical activity in high-risk hepatoblastoma

Area of Science:

• Oncology
• Pharmacology

Background:

• Relapsed and metastatic hepatoblastoma has limited treatment options.
• Polo-like kinase 1 (PLK1) is overexpressed in hepatoblastoma.
• Volasertib targets PLK1 and inhibits cancer cell proliferation.

Purpose of the Study:

• To evaluate volasertib's efficacy against hepatoblastoma.
• To investigate the combination therapy of volasertib and irinotecan for hepatoblastoma.

Main Methods:

• Chemical screening to identify novel agents.
• In vitro and in vivo studies to assess drug efficacy.
• Targeting PLK1 pathway for cancer treatment.

Main Results:

• Volasertib inhibited hepatoblastoma cell growth in vitro while sparing normal hepatocytes.
• The combination of volasertib and irinotecan showed significant in vitro and in vivo efficacy.
• PLK1 inhibition by volasertib prevents mitotic progression and induces cell death.

Conclusions:

• Volasertib is a potential therapeutic agent for hepatoblastoma.
• Combination therapy with volasertib and irinotecan shows promise for relapsed hepatoblastoma.
• Further preclinical and clinical studies are warranted for this combination therapy.